Itziar Irurzun-Arana - AstraZeneca | 人才画像

基本信息

Career Trajectory

Bio

Itziar Irurzun-Arana currently works as a clinical pharmacometrician at AstraZeneca (Cambridge, UK). Itziar does research in Pharmacometrics, Systems Pharmacology and mathematical modeling & simulation.

Research Interests

Papers共 30 篇Author StatisticsCo-AuthorSimilar Experts

By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选

Abstract RF01-01: SERENA-3: A Randomized Pre-Surgical Window of Opportunity Study Assessing Dose and Duration of Camizestrant Treatment in Post-Menopausal Women with ER-positive, HER2-negative Primary Breast Cancer

J.F.R. Robertson, Teimuraz Gogitidze, Zaza Katashvili,Juan Enrique Bargalló Rocha,Ekaterine Arkania,I. K. Moppett,Kwok‐Leung Cheung,Gia Nemsadze,Maxine Ajimi,Itziar Irurzun‐Arana,Justin P.O. Lindemann,Teresa Klinowska,Alastair Mathewson,Christopher J. Morrow,Myria Nikolaou,Giorgi Dzagnidze

Cancer Researchno. 9_Supplement (2024): RF01-01

Cited0Views0Bibtex

A Machine Learning Approach to Population Pharmacokinetic Modelling Automation

Samuel Richardson,Itziar Irurzun Arana,Andrzej Nowojewski,Diansong Zhou,Jacob Leander,Weifeng Tang, Richard Dearden,Megan Gibbs

crossref（2024）

Cited0Views0Bibtex

SERENA-3: A Randomized Pre-Surgical Window of Opportunity Study Assessing Dose and Duration of Camizestrant Treatment in Post-Menopausal Women with ER-positive, HER2-negative Primary Breast Cancer

John Robertson, Teimuraz Gogitidze, Zaza Katashvili,Juan Enrique Bargallo Rocha,Ekaterine Arkania,Iain Moppett,Kwok-Leung Cheung,Gia Nemsadze,Maxine Ajimi,Itziar Irurzun-Arana,Justin Lindemann,Teresa Klinowska,Alastair Mathewson,Christopher Morrow,Myria Nikolaou,Giorgi Dzagnidze

CANCER RESEARCHno. 9 (2024)

Cited0Views0Bibtex

Abstract RF01-01: SERENA-3: A randomized pre-surgical window of opportunity study assessing dose and duration of camizestrant treatment in post-menopausal women with ER-positive, HER2-negative primary breast cancer

Cancer Research（2024）

Cited0Views0Bibtex

Abstract P3-07-28: SERENA-1: Updated Analyses from a Phase 1 Study of the Next Generation Oral Selective Estrogen Receptor Degrader Camizestrant (AZD9833) Combined with Abemaciclib, in Women with ER-positive, HER2-negative Advanced Breast Cancer

Cancer Research（2023）

Cited1Views0Bibtex

SERENA-1: Updated Analyses from a Phase 1 Study of the Next Generation Oral Selective Estrogen Receptor Degrader Camizestrant (AZD9833) Combined with Abemaciclib, in Women with ER-positive, HER2-negative Advanced Breast Cancer

CANCER RESEARCHno. 5 (2023)

Cited0Views0Bibtex

Author Statistics

Co-Author

Co-Institution

D-Core

合作者
学生
导师

No result temporarily, you can search similar Scholar with the same research interest

Data Disclaimer

The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn